Targeting interleukin-1β in CAPS (cryopyrin-associated periodic) syndromes. What did we learn?

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 77-80

  Koné Paut, Isabelle ^a   Piram, Maryam ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anakinra; Canakinumab; Cryopyrin associated periodic disorders; Rilonacept; Treatment

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

BINDING COMPETITION; BODY WEIGHT; CINCA SYNDROME; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EUROPE; HUMAN; INJECTION SITE PAIN; MULTICENTER STUDY (TOPIC); OFF LABEL DRUG USE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; QUALITY OF LIFE; RELAPSE; REVIEW; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866844951     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.026     Document Type: Review

References (27)

1. Touitou I., Kone-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829.
2. Agostini L., Martinon F., Burns K., McDermott M.F., Hawkins P.N., Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20:319-325.
3. Feldmann J., Prieur A., Quartier P., Berquin P., Certain S., Cortis E., et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002, 71:198-203.
4. Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001, 29:301-305.
5. Janssen R., Verhard E., Lankester A., ten Cate R., van Dissel J.T. Enhanced interleukin-1β and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004, 50:3329-3333.
6. Lachmann H.J., Lowe P., Felix S.D., Rordorf C., Leslie K., Madhoo S., et al. In vivo regulation of interleukin 1 beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009, 206:1029-1036.
7. Muckle T.J., Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962, 31:235-248.
8. Prieur A.M., Griscelli C., Lampert F., Truckenbrodt H., Guggenheim M.A., Lovell D.J., et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987, 66:57-68.
9. Hoffman H.M., Wanderer A.A., Broide D.H. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001, 108:615-620.
10. Tran T.A., Kone-Paut I., Marie I., Ninet J., Cuisset L., Meinzer U., et al. Muckle-Wells syndrome and male hypofertility: a case series. Arthritis Rheum 2012, [Electronic publication ahead of print].
11. Aksentijevich I.D., Putnam C., Remmers E.F., Mueller J.L., Le J., Kolodner R.D., et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007, 56:1273-1285.
12. Milhavet F., Cuisset L., Hoffman H.M., Slim R., El-Shanti H., Aksentijevich I., et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008, 29:803-808.
13. Jesus A.A., Silva C., Segundo G., Aksentijevich I., Fujihira E., Watanabe M., et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol 2008, 28:134-138.
14. Jeru I., Marlin S., Le Borgne G., Cochet E., Normand S., Duquesnoy P., et al. Functional consequences of a germline mutation in the leucine-rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder. Arthritis Rheum 2010, 62:1176-1185.
15. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
16. Hawkins P.N., Lachmann H.J., McDermott M.F. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003, 348:2583-2584.
17. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004, 364:1779-1785.
18. Goldbach-Mansky R., Dailey N.J., Canna S.W., Gelabert A., Jones J., Rubin B.I., et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 inhibition. N Engl J Med 2006, 355:581-592.
19. Kuemmerle-Deschner J.B., Tyrrell P.N., Koetter I., Wittkowski H., Bialkowski A., Tzaribachev N., et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011, 63:840-849.
20. Hoffman H.M., Throne M.L., Amar N.J., Sebai M., Kivitz A.J., Kavanaugh A., et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008, 58:2443-2452.
21. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., Leslie K.S., Hachulla E., Quartier P., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
22. Stych B., Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008, 24:1577-1582.
23. Kone-Paut I., Lachmann H.J., Kuemmerle-Deschner J.B., Hachulla E., Leslie K.S., Mouy R., et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011, 13:R202.
24. Lepore L., Paloni G., Caorsi R., Alessio M., Rigante D., Ruperto N., et al. Follow-up and quality of life of patients with cryoprin-associated periodic syndromes treated with Anakinra. J Pediatr 2010, 157:310-5.e1.
25. Neven B., Marvillet I., Terrada C., Ferster A., Boddaert N., Couloignier V., et al. Arthritis Rheum 2010, 62:258-267. b.
26. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., Hawkins P.N., Tran T.A., Bader-Meunier B., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
27. Miyamae T., Inaba Y., Nishimura G., Kikuchi M., Kishi T., Hara R., et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr Rheumatol Online J 2010 Mar 16, 8:9.